Equities

CI Medical Co Ltd

3540:TYO

CI Medical Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)1,064.00
  • Today's Change14.00 / 1.33%
  • Shares traded26.80k
  • 1 Year change+56.70%
  • Beta1.5650
Data delayed at least 20 minutes, as of Nov 15 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

C.I.MEDICAL CO.,LTD. is a Japan-based company engaged in mail order sales to dental clinics, dental laboratories and other various medical institutions. Mail order sales segment sells products purchased from domestic and overseas wholesalers and manufacturers to domestic dental clinic and other healthcare professionals. Mail order distributions include Ci Medical for dental clinic, nurse+care for clinic, DENTAL LABO for dental laboratory, Vet for veterinary medical materials and pharmaceutical, FreshCare for nursing care facilities and welfare facilities, Medical catalog for hospitals and general clinics, Demiline dental clinic catalog for dental clinics, dental fit for patients and the MEX business for pharmacies. It also provides computer aided design (VAD) and computer aided manufacturing (CAM) dental technology production business, dental magazine publishing business, solar power generation business, and website creation agency business for dental clinics and dental laboratories.

  • Revenue in JPY (TTM)47.75bn
  • Net income in JPY1.43bn
  • Incorporated2000
  • Employees473.00
  • Location
    CI Medical Co Ltd152, Ni, Fukushima-machiNOMI-SHI 929-0112JapanJPN
  • Phone+81 762788802
  • Fax+81 761270780
  • Websitehttps://ci-medical.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rion Co Ltd26.67bn2.59bn30.55bn1.03k11.761.018.321.15210.52210.522,165.882,443.260.72271.734.1225,990,020.007.036.278.177.2550.4050.299.728.852.41----28.117.793.8647.395.7825.244.56
Mizuho Medy Co Ltd10.99bn3.50bn30.81bn180.008.811.918.292.80183.56183.56576.85846.830.59721.692.6061,046,260.0019.0131.4621.2539.7871.8874.8531.8333.647.62--0.0034.83-37.4911.34-51.8532.64-17.7432.85
Nippon Care Supply Co., Ltd.30.49bn1.67bn31.21bn1.33k17.851.843.751.02107.69107.691,962.131,045.341.21119.7527.3122,853,900.006.657.619.629.9435.2037.585.496.780.6264--0.160556.7510.4310.474.212.0724.048.76
Win-Partners Co Ltd80.84bn1.98bn38.53bn629.0018.231.5817.640.476669.2969.292,830.28798.131.8824.194.87128,518,700.004.604.398.318.0612.2812.502.452.681.68----63.188.762.01-10.33-7.0140.619.34
France Bed Holdings Co Ltd60.04bn3.21bn47.23bn1.78k13.901.105.440.786788.4888.481,653.981,114.400.9223.166.3533,670,780.004.933.856.335.2454.1452.365.354.412.01--0.260549.980.97822.7015.993.81-1.019.30
Medikit Co Ltd22.29bn3.03bn51.98bn966.0014.720.964111.752.33197.42197.421,453.363,015.350.41923.584.2923,074,350.005.695.756.406.3138.7540.0513.5814.084.774,935.020.0038.881.133.387.153.56-0.600512.20
CI Medical Co Ltd47.75bn1.43bn53.20bn473.0037.122.6015.861.1128.6628.66955.00408.471.164.2814.43100,945,000.003.5510.837.1915.6525.7327.733.066.060.524200.360.483512.836.3812.07-17.419.3877.2413.65
TAUNS Laboratories Inc18.43bn5.77bn57.39bn271.009.854.168.903.1157.7457.74184.35136.67------68,025,330.00--------67.80--31.32--1.16341.330.4111--17.62--90.26------
Japan Eyewear Holdings Co Ltd15.43bn3.01bn61.78bn542.0020.654.2213.484.00124.12124.12637.46607.450.45652.1913.2528,459,410.008.90--10.18--78.21--19.50--1.1810.040.5285--26.17--659.25------
Shofu Inc37.52bn4.46bn75.58bn1.37k16.881.8118.482.01125.14125.141,052.791,168.620.79511.449.4927,406,870.009.486.1510.627.0059.7157.7611.928.122.89--0.004831.8410.747.0816.5924.935.0321.94
Intermestic Inc-100.00bn-100.00bn77.94bn1.84k--7.31----------348.56------------------------1.10--0.494--11.12--102.26------
Data as of Nov 15 2024. Currency figures normalised to CI Medical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

1.94%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Aug 2024630.00k1.26%
Hayate Partners Pte Ltd.as of 30 Jun 2024250.00k0.50%
Nikko Asset Management Co., Ltd.as of 19 Dec 202285.00k0.17%
Mitsubishi UFJ Asset Management Co., Ltd.as of 19 Sep 20232.50k0.01%
Sumitomo Mitsui DS Asset Management Co., Ltd.as of 10 Jul 20232.00k0.00%
Asset Management One Co., Ltd.as of 29 Aug 20230.000.00%
TORANOTEC Asset Management Co., Ltd.as of 20 Jul 20230.000.00%
More ▼
Data from 21 Mar 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.